Skip to main content
Clinical Trials/NCT04792658
NCT04792658
Unknown
Not Applicable

Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation in Neuropsychiatric Disease

Assiut University0 sites100 target enrollmentMarch 10, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Psychiatric Disorder
Sponsor
Assiut University
Enrollment
100
Primary Endpoint
measure of risk factor of DSM 5 psychiatric disorders associated with long term of benzodiazepine use
Last Updated
5 years ago

Overview

Brief Summary

Benzodiazepines are usually a secondary drug of abuse-used mainly to augment the high received from another drug or to offset the adverse effects of other drugs. Few cases of addiction arise from legitimate use of benzodiazepines. Pharmacologic dependence, a predictable and natural adaptation of a body system long accustomed to the presence of a drug, may occur in patients taking therapeutic doses of benzodiazepines. However, this dependence, which generally manifests itself in withdrawal symptoms upon the abrupt discontinuation of the medication, may be controlled and ended through dose tapering, medication switching, and/or medication augmentation. Due to the chronic nature of anxiety, long-term low-dose benzodiazepine treatment may be necessary for some patients; this continuation of treatment should not be considered abuse or addiction.

previous study reported that The results of the study are important in that they corroborate the mounting evidence that a range of neuropsychological functions are impaired as a result of long-term benzodiazepine use, and that these are likely to persist even following withdrawal. The findings highlight the residual neurocognitive compromise associated with long-term benzodiazepine therapy as well as the important clinical implications of these results.

Registry
clinicaltrials.gov
Start Date
March 10, 2021
End Date
September 20, 2023
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gellan Karamalllah Ramadan Ahmed

lecturer, resarcher OF Neurology and Psychiatry department

Assiut University

Eligibility Criteria

Inclusion Criteria

  • age from 18 years to 50 years
  • No history of neurological or medical illness

Exclusion Criteria

  • intelligence score more than 80

Outcomes

Primary Outcomes

measure of risk factor of DSM 5 psychiatric disorders associated with long term of benzodiazepine use

Time Frame: through study completion, an average of 1 year

measure the prevalence of DSM 5 psychiatric disorders associated with long term of benzodiazepine use

Time Frame: through study completion, an average of 1 year

Similar Trials